Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.

Studied

This full-text mechanistic study tested tirzepatide signaling and receptor occupancy using engineered human receptor cell lines and isolated mouse pancreatic islets.

Who / model

Models included HEK293 cells expressing human GIP or GLP-1 receptors and islets from genetically modified mice; this was not a human treatment trial.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Tirzepatide matched native GIP at the GIP receptor but showed weaker GLP-1-receptor potency, favoring cAMP signaling over arrestin recruitment and producing less GLP-1-receptor internalization.

Limits

Cell and mouse-islet mechanisms cannot establish human clinical benefit; the authors said translational relevance still required clinical investigation.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary